Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
A series of naphthalenyloxy-arylpropylamines have been prepared and are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake. One member of this series, duloxetine (Cymbalta) has proven to be effective in clinical trials for the treatment of depression.
Bymaster
F P
FP
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Beedle
E E
EE
Findlay
J
J
Gallagher
P T
PT
Krushinski
J H
JH
Mitchell
S
S
Robertson
D W
DW
Thompson
D C
DC
Wallace
L
L
Wong
D T
DT
D000928:Antidepressive Agents / Q000138:chemical synthesis / Q000627:therapeutic use; D001665:Binding Sites; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy; D000068736:Duloxetine Hydrochloride; D006801:Humans; D007700:Kinetics; D009638:Norepinephrine / Q000037:antagonists & inhibitors*; D017367:Selective Serotonin Reuptake Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013876:Thiophenes / Q000737:chemistry* / Q000627:therapeutic use
D000928:Antidepressive Agents; D000068736:Duloxetine Hydrochloride; D009638:Norepinephrine; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes